Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | GOT1 | P17174 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | STS | P08842 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | JAK1 | P23458 | 2/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | TYK2 | P29597 | 1/20 | 0.41 |
| ▸ | JAK3 | P52333 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | KIT | P10721 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5704915 | 0.86 | DRD2 (0.50) | MAPTGAAGOT1MEN1KMT2A | |
| SCHEMBL5704985 | 0.85 | GOT1 (0.45) | MAPTGOT1ALDH1A1LMNASTS | |
| SCHEMBL31210541 | 0.85 | GOT1 (0.47) | MAPTGOT1MEN1KMT2AALDH1A1 | |
| SCHEMBL31210747 | 0.83 | GOT1 (0.46) | MAPTGOT1MEN1KMT2AALDH1A1 | |
| SCHEMBL6381506 | 0.82 | STS (0.46) | MAPTMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL25337613 | 0.81 | BACE1 (0.44) | MAPTGAAGOT1MEN1KMT2A | |
| SCHEMBL5704899 | 0.80 | DRD2 (0.50) | MAPTGAAGOT1MEN1KMT2A | |
| SCHEMBL1537795 | 0.78 | GAA (0.60) | MAPTGAAGOT1RECQL | |
| SCHEMBL30885791 | 0.78 | GAA (0.60) | MAPTGAAGOT1RECQL | |
| SCHEMBL5704805 | 0.78 | GOT1 (0.60) | MAPTGAAGOT1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1335722-B1 | INDOLYL-SULFONYL- COMPOUNDS USEFUL IN THE TREATMENT OF CNS DISORDERS | SMITHKLINE BEECHAM PLC (GB) | 2006-08-30 | — | — | EP | disclosed |
| US-20050176705-A1 | Compounds useful in the treatment of cns disorders | SMITHKLINE BEECHAM P.L.C. (GB) | 2005-08-11 | — | — | US | disclosed |
| EP-1335722-A2 | COMPOUNDS USEFUL IN THE TREATMENT OF CNS DISORDERS | SMITHKLINE BEECHAM PLC (GB) | 2003-08-20 | — | — | EP | disclosed |
| WO-2002041889-A2 | INDOLSULFONYL COMPOUNDS USEFUL IN THE TREATMENT OF CNS DISORDERS | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176705-A1 | Compounds useful in the treatment of cns disorders | SLC18A2, CNR2, TPH2 | MAPT 82/4885GAA 1510/4885GOT1 2552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.